Related references
Note: Only part of the references are listed.Characterization of Intracellular Signaling Mediated by Human Somatostatin Receptor 5: Role of the DRY Motif and the Third Intracellular Loop
Erika Peverelli et al.
ENDOCRINOLOGY (2009)
Coexpression of Dopamine and Somatostatin Receptor Subtypes in Corticotroph Adenomas
Christiaan de Bruin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies
Gherardo Mazziotti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Treatment of Pituitary-Dependent Cushing's Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial
M. Boscaro et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Differential Effects of Octreotide and Pasireotide on Somatostatin Receptor Internalization and Trafficking in Vitro
Sarah Lesche et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
The Medical Treatment of Cushing's Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery
Rosario Pivonello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Differential regulation of human dopamine D-2 and somatostatin receptor subtype expression by glucocorticoids in vitro
C. de Bruin et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2009)
Somatostatin Receptor Subtypes 2 and 5 Are Associated with Better Survival in Well-Differentiated Endocrine Carcinomas
Vito D. Corleto et al.
NEUROENDOCRINOLOGY (2009)
Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours
Nicole Unger et al.
CLINICAL ENDOCRINOLOGY (2008)
Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study
Tullio Florio et al.
ENDOCRINE-RELATED CANCER (2008)
Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR
Giselle F. Taboada et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Samatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas
Alessandra Fusco et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival
Dik J. Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Selective agonism in somatostatin receptor signaling and regulation
Agnes Schonbrunn
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2008)
Intracellular trafficking of somatostatin receptors
Stefan Jacobs et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2008)
Function and expression of somatostatin receptors of the endocrine pancreas
Mathias Z. Strowski et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2008)
Genetic abnormalities of somatostatin receptors in pituitary tumors
A. Lania et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2008)
Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization
Michael Grant et al.
MOLECULAR ENDOCRINOLOGY (2008)
The third intracellular loop of the human somatostatin receptor 5 is crucial for arrestin binding and receptor internalization after somatostatin stimulation
Erika Peverelli et al.
MOLECULAR ENDOCRINOLOGY (2008)
Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: A chemogenomics approach
Rainer E. Martin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2
Nadder Sharif et al.
ENDOCRINOLOGY (2007)
Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: A possible marker for predicting long-term response to octreotide therapy
Ai Yoshihara et al.
ENDOCRINE JOURNAL (2007)
Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion:: An in vitro study on isolated human pancreatic islets
Vandana Singh et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Rationale for the use of somatostatin analogs as antitumor agents
C. Susini et al.
ANNALS OF ONCOLOGY (2006)
The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies
Dermot O'Toole et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas
Dalia L. Batista et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2
E. Ferrante et al.
ENDOCRINE-RELATED CANCER (2006)
Regulation of neuronal nitric-oxide synthase activity by somatostatin analogs following SST5 somatostatin receptor activation
Pierre Cordelier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas
SV de Sá et al.
ENDOCRINE-RELATED CANCER (2006)
Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance
AB Atkinson et al.
CLINICAL ENDOCRINOLOGY (2005)
Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells
J van der Hoek et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2005)
The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients
J van der Hoek et al.
CLINICAL ENDOCRINOLOGY (2005)
Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly
M Filopanti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly
PM Ma et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion
A Ben-Shlomo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5
LJ Hofland et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro
LJ Hofland et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Molecular targets in pituitary tumours
AP Heaney et al.
NATURE REVIEWS CANCER (2004)
Expression and distribution of somatostatin receptor subtypes in the pancreatic islets of mice and rats
E Ludvigsen et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2004)
Role of amphiphysin II in somatostatin receptor trafficking in neuroendocrine cells
P Sarret et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients
J van der Hoek et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Evolving concepts in the quest for advanced therapeutic analogues of somatostatin
MD Culler
DIGESTIVE AND LIVER DISEASE (2004)
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system
K Öberg et al.
ANNALS OF ONCOLOGY (2004)
The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion
RD Murray et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas
M Filopanti et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2004)
Differential β-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes
G Tulipano et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Dopamine receptor expression and function in corticotroph pituitary tumors
R Pivonello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Lanreotide 60 mg, a new long-acting formulation: Effectiveness in the chronic treatment of acromegaly
R Attanasio et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Somatostatin receptors
LN Moller et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2003)
A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential
I Lewis et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Primary medical therapy for acromegaly
MC Sheppard
CLINICAL ENDOCRINOLOGY (2003)
Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs
I Shimon
ENDOCRINE (2003)
Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas
A Colao et al.
ENDOCRINE (2003)
The pathophysiological consequences of somatostatin receptor internalization and resistance
LJ Hofland et al.
ENDOCRINE REVIEWS (2003)
SOM230: A new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs
G Weckbecker et al.
ENDOCRINOLOGY (2002)
Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size
JS Bevan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Dopamine receptor agonists for treating prolactinomas
A Colao et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2002)
SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile
C Bruns et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002)
Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors -: A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis
M Papotti et al.
VIRCHOWS ARCHIV (2002)
Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies
H Kulaksiz et al.
GUT (2002)
A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs:: in vivo and in vitro studies
A Saveanu et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2001)
Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands
JC Reubi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2001)
Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours
T Aparicio et al.
EUROPEAN JOURNAL OF CANCER (2001)
Cellular biology of somatostatin receptors
Z Csaba et al.
NEUROPEPTIDES (2001)
Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity
M Rocheville et al.
SCIENCE (2000)
Identification and characterization of subtype selective somatostatin receptor agonists
SP Rohrer et al.
JOURNAL OF PHYSIOLOGY-PARIS (2000)
Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers
M Rocheville et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
